Terns Pharmaceuticals (TERN) News Today $4.04 -0.10 (-2.30%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Terns Pharmaceuticals Appoints Robert Azelby to Board of DirectorsFebruary 20 at 4:05 PM | globenewswire.comTerns Pharmaceuticals stock hits 52-week low at $4.16February 13, 2025 | msn.comTerns Pharmaceuticals announces CFO transition and consulting agreementFebruary 6, 2025 | msn.comTerns Pharmaceuticals CFO Resignation and Leadership TransitionFebruary 6, 2025 | tipranks.comTerns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comNovartis CEO discusses search for obesity deals with WSJFebruary 4, 2025 | markets.businessinsider.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Insider Melita Sun Jung Buys 2,250 SharesFebruary 4, 2025 | insidertrades.comMelita Sun Jung Acquires 2,250 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) insider Melita Sun Jung purchased 2,250 shares of the stock in a transaction that occurred on Saturday, November 30th. The stock was bought at an average cost of $5.11 per share, for a total transaction of $11,497.50. Following the acquisition, the insider now directly owns 2,250 shares in the company, valued at $11,497.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.February 3, 2025 | marketbeat.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)February 3, 2025 | globenewswire.comTerns Pharmaceuticals stock hits 52-week low at $4.32January 29, 2025 | msn.comNovo Nordisk's Ozempic gets FDA approval for kidney diseaseJanuary 28, 2025 | msn.comTerns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Insider Sells $25,586.51 in StockJanuary 7, 2025 | insidertrades.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Insider Emil Kuriakose Sells 4,481 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) insider Emil Kuriakose sold 4,481 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.71, for a total value of $25,586.51. Following the sale, the insider now owns 54,269 shares in the company, valued at approximately $309,875.99. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.January 6, 2025 | marketbeat.comJill M. Quigley Sells 6,240 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) Director Jill M. Quigley sold 6,240 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $5.72, for a total value of $35,692.80. Following the sale, the director now directly owns 8,760 shares of the company's stock, valued at approximately $50,107.20. This trade represents a 41.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.January 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola Sells 8,129 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Mark J. Vignola sold 8,129 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $5.72, for a total transaction of $46,497.88. Following the sale, the chief financial officer now directly owns 83,811 shares of the company's stock, valued at approximately $479,398.92. This trade represents a 8.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.January 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill M. Quigley Sells 8,760 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) Director Jill M. Quigley sold 8,760 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $5.79, for a total transaction of $50,720.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.January 6, 2025 | marketbeat.comMark J. Vignola Sells 9,059 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Mark J. Vignola sold 9,059 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $5.80, for a total value of $52,542.20. Following the transaction, the chief financial officer now directly owns 74,752 shares in the company, valued at $433,561.60. This represents a 10.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.January 6, 2025 | marketbeat.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)January 2, 2025 | globenewswire.comTerns Pharmaceuticals Positioned for Success with Promising Oral Therapy TERN-601 Amid Novo Nordisk’s SetbackDecember 20, 2024 | markets.businessinsider.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Down 4.7% - Time to Sell?Terns Pharmaceuticals (NASDAQ:TERN) Shares Down 4.7% - Here's What HappenedDecember 18, 2024 | marketbeat.comIs Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?December 16, 2024 | insidermonkey.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Stake Reduced by Fmr LLCFmr LLC decreased its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 57.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,172,524 shares of the company's stock after selling 1,594,572 shares duringDecember 12, 2024 | marketbeat.comTerns Pharmaceuticals CEO & Director Acquires 423% More StockDecember 11, 2024 | uk.finance.yahoo.comAmy L. Burroughs Purchases 15,450 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockDecember 10, 2024 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Terns Pharmaceuticals (TERN)December 6, 2024 | markets.businessinsider.comWalleye Capital LLC Takes $1.55 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Walleye Capital LLC acquired a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 185,795 shares of the company's stock, valued at approDecember 5, 2024 | marketbeat.comTerns's stock soars as analysts cheer leukemia data — and predict more gainsDecember 4, 2024 | marketwatch.comParkman Healthcare Partners LLC Grows Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Parkman Healthcare Partners LLC increased its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 39.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 545,751 shares of the company's stock after buying an additionDecember 4, 2024 | marketbeat.com168,564 Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Acquired by Cinctive Capital Management LPCinctive Capital Management LP bought a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 168,564 shares of the company's stock, valued at approximately $1,406,000. CDecember 4, 2024 | marketbeat.comTerns Pharmaceuticals price target raised to $20 from $17 at OppenheimerDecember 3, 2024 | markets.businessinsider.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)December 2, 2024 | globenewswire.comQuantbot Technologies LP Purchases 117,079 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Quantbot Technologies LP raised its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 3,114.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 120,838 shares of the company's stoDecember 2, 2024 | marketbeat.comBellevue Group AG Acquires New Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Bellevue Group AG acquired a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,042,135 shares of the company's stock, valDecember 1, 2024 | marketbeat.comAcuta Capital Partners LLC Has $4.06 Million Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Acuta Capital Partners LLC boosted its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 31.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 487,000 shares of the company's stock after acquiring aNovember 28, 2024 | marketbeat.comWeight-loss-drug makers’ stocks get a boost from new Biden coverage proposal, but will it hold up?November 26, 2024 | msn.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued aNovember 25, 2024 | marketbeat.comTerns Pharmaceuticals on the Brink of Innovation with Upcoming TERN-701 Data ReleaseNovember 22, 2024 | markets.businessinsider.comTelemark Asset Management LLC Purchases Shares of 300,000 Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Telemark Asset Management LLC acquired a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 300,000 shares of the company's stock, valued at approximatelNovember 22, 2024 | marketbeat.com104,535 Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Bought by Quest Partners LLCQuest Partners LLC purchased a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 104,535 shares of the company's stock, valued at apNovember 21, 2024 | marketbeat.comTerns Pharmaceuticals Appoints Heather Turner to BoardNovember 19, 2024 | markets.businessinsider.comTerns Pharmaceuticals Appoints Heather Turner, J.D., to Board of DirectorsNovember 18, 2024 | globenewswire.comTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 8.7% - Should You Sell?Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 8.7% - Should You Sell?November 15, 2024 | marketbeat.comWe Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business GrowthNovember 15, 2024 | finance.yahoo.comWhat is HC Wainwright's Forecast for TERN FY2024 Earnings?Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Terns Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per shaNovember 15, 2024 | marketbeat.comBrokers Issue Forecasts for TERN Q1 EarningsTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Terns Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst E. Arce anticipates that the company will earn ($November 14, 2024 | marketbeat.comTerns Pharmaceuticals: Promising Clinical Developments and Strong Financial Position Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comPromising Phase 1/2 Study and Strong Financials Drive Buy Rating for Terns PharmaceuticalsNovember 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Revolution Medicines (RVMD)November 8, 2024 | markets.businessinsider.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by AnalystsTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have issuedOctober 31, 2024 | marketbeat.com Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address TERN Media Mentions By Week TERN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TERN News Sentiment▼0.000.60▲Average Medical News Sentiment TERN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TERN Articles This Week▼13▲TERN Articles Average Week Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ardelyx News Today Indivior News Today Nurix Therapeutics News Today Vir Biotechnology News Today Syndax Pharmaceuticals News Today Arvinas News Today ANI Pharmaceuticals News Today Day One Biopharmaceuticals News Today Adaptive Biotechnologies News Today Arcus Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TERN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
